Latest

1 story

Hide weekly roundups

Friday, September 11

Trial tests Tislelizumab plus Anlotinib as consolidation therapy in limited-stage SCLC

Trial updateBeiGene Sino Biopharmaceutical

Biotech intelligence from primary sources. Every story is an original summary of a public record, linked to its source. Not investment advice.

Terms Privacy hello@readthrough.news

readthrough is a product of JAMN Ventures, LLC.